Peel Hunt restated their hold rating on shares of Abcam (LON:ABC) in a research note released on Monday.

Other equities research analysts have also recently issued reports about the company. Numis Securities reaffirmed a hold rating on shares of Abcam in a research note on Tuesday, September 11th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of Abcam in a research note on Wednesday, January 2nd.

Shares of ABC stock opened at GBX 1,167 ($15.25) on Monday. Abcam has a 52-week low of GBX 9.73 ($0.13) and a 52-week high of GBX 1,290 ($16.86).

In related news, insider Jonathan Simon Milner bought 187,790 shares of the business’s stock in a transaction dated Thursday, December 6th. The shares were purchased at an average cost of GBX 1,060 ($13.85) per share, with a total value of £1,990,574 ($2,601,037.50). Also, insider Suzanne Smith bought 864 shares of the business’s stock in a transaction dated Wednesday, November 7th. The stock was bought at an average cost of GBX 1,219 ($15.93) per share, for a total transaction of £10,532.16 ($13,762.13).

About Abcam

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Featured Article: Mutual Funds

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.